The notices it replaced
- Reissues: PA-21-262 PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 2 steps back: PA-20-265 PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 3 steps back: PA-19-270 PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed
- 4 steps back: PA-18-575 PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 5 steps back: PA-17-303 PHS 2017-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 6 steps back: PA-16-303 PHS 2016-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 7 steps back: PA-15-270 PHS 2015-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 8 steps back: PA-14-072 PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]
- 9 steps back: PA-13-235 Reissue PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 10 steps back: PA-13-089 PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 11 steps back: PA-12-089 PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 12 steps back: PA-11-097 PHS 2011-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 13 steps back: PA-10-051 PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 14 steps back: PA-09-081 PHS 2009-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Replaced by PA-23-232.
Who won it before
1,925 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $657,676,719 in first-year total cost, median $273,556.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-T (10)]101
- Special Emphasis Panel[ZRG1 OTC-T (10)]81
- Special Emphasis Panel[ZRG1 ETTN-G (12)]62
- Special Emphasis Panel[ZRG1 ETTN-M (11)]55
- Special Emphasis Panel[ZRG1 BCMB-G (10)]52
Most frequent institutions
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC19
- L2 DIAGNOSTICS, LLC13
- MEDOSOME BIOTEC, LLC10
- ARREVUS, INC.8
- KLEIN BUENDEL, INC.8
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum2R42AI162385-03 | RICCIARDI, ROBERT PAUL | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $1,039,551 | ZRG1 |
| 2024 | A New Small-Molecule Kinase Inhibitor for Airway Disease2R42HL149523-02 | BROSCHAT, KAY O | NUPEAK THERAPEUTICS, INC., MO | $1,018,383 | ZRG1 |
| 2024 | Prevention of corneal transplant rejection using AAV-BDRK-401 therapy2R42EY031625-02 | GILGER, BRIAN CHIRSCH, MATTHEW LOUIS | BEDROCK THERAPEUTICS, INC., NC | $975,387 | ZRG1 |
| 2024 | A New Anti-inflammatory Therapy for Ischemic Stroke2R42HL156322-02A1 | LIANG, BRUCE | CORNOVUS PHARMACEUTICALS, INC., CT | $934,548 | ZRG1 |
| 2024 | Development of an integrated smartphone-nanosensor platform for onsite biomonitoring of exposure to pesticides2R42ES032388-02A1 | WANG, JUN | NANODIAGNOSTIC TECHNOLOGY, LLC, NC | $915,031 | ZRG1 |
| 2024 | Automated microfluidic device for blood analysis in neonates2R42HD100251-02 | GONZALEZ-SUAREZ, ALAN M | SERSENSE, INC., MN | $780,138 | ZRG1 |
| 2024 | Development of a Novel AAV9 Gene Replacement Therapy for Neurofibromatosis Type 21R41NS135883-01 | HENWOOD, NICOLENAEIMI KARAROUDI, MEISAM | MERLIN THERAPEUTICS INC, PA | $699,559 | ZRG1 |
| 2024 | STTR Phase II - Development of a visual-to-tactile conversion system for automating the tactile graphic generation process2R42EY031628-02A1 | PALANI, HARI PRASATH | UNAR LABS, LLC, ME | $674,598 | ZRG1 |
| 2024 | Novel brain-penetrant drugs for translation-targeting therapeutics of Alzheimer’s disease1R41AG085859-01 | CHEN, XIAN | TRANSCHROMIX, LLC., NC | $497,218 | ZRG1 |
| 2024 | Single telomere length analysis using DNA array and FISH: a low-cost and accurate test for telomere-associated diseases1R41AG085701-01 | WANG, YINGZHENG, YUN-LING | TELOHEALTHDX LLC, MD | $448,961 | ZRG1 |
| 2024 | Preventing chemotherapy-related toxicities and infections with a novel phosphorylated triblock copolymer1R41CA287593-01 | ALVERDY, JOHN CHENNESSEY, PATRICK | COVIRA SURGICAL, IL | $400,000 | ZRG1 |
| 2024 | Stroma-penetrating nanomedicine to improve treatment for pancreatic cancer1R41CA278033-01A1 | EICHINGER, KATHERINE MARIE | DUO ONCOLOGY INC, PA | $399,970 | ZRG1 |
| 2024 | Multi-Modality Optical Molecular Imaging System for Preclinical Cancer Models1R42CA287798-01 | GULSEN, GULTEKINMOY, AUSTIN | TRIFOIL IMAGING, CA | $399,491 | ZRG1 |
| 2024 | Innovative Point-of-Care Solutions for Long-term Alcohol Biomarkers1R41AA031429-01 | NEILSEN, PAUL O | ECHELON BIOSCIENCES, INC., UT | $399,293 | ZRG1 |
| 2024 | Antibody-based prertargeted alpha particle therapy for ovarian cancer1R42CA287696-01 | HOUGHTON, JACOBSCHULTZ, MICHAEL KING | VIEWPOINT MOLECULAR TARGETING, INC., IA | $391,553 | ZRG1 |
| 2024 | Development of a mobile harm reduction treatment for alcohol use disorder (mHaRT-A)1R41AA031393-01 | COLLINS, SUSAN E | HART3S - A SOCIAL PURPOSE CORPORATION, WA | $369,597 | ZRG1 |
| 2024 | Tethered Enzyme Technology for PoC and At-home Real-time Monitoring of Liver Function1R41TR004880-01 | COHEN, ROYFISCHELL, DAVID | TET MEDICAL, NY | $324,962 | ZRG1 |
| 2024 | Novel Integrated Platform to Quantitate Rejuvenation in vivo1R41AG085951-01 | EGAN, BRIAN STANLEYJELINEK, MARY ANNETERSKIKH, ALEXEY V | ACTIVE MOTIF, INC., CA | $314,262 | ZRG1 |
| 2024 | Rapid Dehydration and Stabilization of Biopharmaceutical Formulations at Room Temperature1R41TR004571-01A1 | MEZHERICHER, MAKSIM | INAEDIS, INC, NJ | $312,634 | ZRG1 |
| 2024 | Computational design and evaluation of peptide-guided protein degraders1R41GM153081-01 | CAMARGO, LUIZ MIGUEL QUINN | UBIQUITX, INC., NY | $306,872 | ZRG1 |
| 2024 | Development of Small Molecule Biomarker-Based Diagnostics for Bacterial Vaginosis1R41AI176963-01A1 | SRINIVASAN, SUJATHA | METABOLITEDX CORP, WA | $306,500 | ZRG1 |
| 2024 | Innovative oral regenerative therapy leveraging immunoregenerative mechanisms.1R41DE033573-01 | GOUDY, STEVEN L | ORIDIVUS LLC, GA | $306,499 | ZRG1 |
| 2024 | Multi-functional magnetic nanorods for constructing theranostic extracellular vesicles for treating myocardial infarction1R41HL169102-01A1 | LI, YUANCHENGLIU, GUANSHU | 5M BIOMED, LLC, GA | $306,433 | ZRG1 |
| 2024 | Epigenetic phenotyping from liquid biopsy for preeclampsia risk classification during the first trimester1R41HL172464-01 | REICHEL, JONATHAN | KANONA, INC., NJ | $306,223 | ZRG1 |
| 2024 | Multi-omic CSF Assay for the Diagnosis of Brain Cancers1R42NS135834-01 | BETTEGOWDA, CHETANCOE, BRIAN | BELAY DIAGNOSTICS, LLC, IL | $303,845 | ZRG1 |
| 2024 | Chimeric antigen receptor (CAR) T cell therapy for severe allergic diseases.1R41AI177157-01A1 | MA, ZHENGYU | CELLERGY PHARMA, DE | $300,000 | ZRG1 |
| 2024 | Development of Inhibitors Against SARS CoV-2 NSP16 Methyltransferase1R41AI177149-01A1 | LI, HONGMIN | LYCHEE BIOSCIENCE LLC, AZ | $299,985 | ZRG1 |
| 2024 | Development of a Pan-COVID-19 Vaccine Candidate1R41AI181134-01 | HU, HAITAO | RNA THERAPEUTICS INC., DE | $299,967 | ZRG1 |
| 2024 | Develop natural compound emodin as a novel therapy for calcific aortic valve disease1R41HL172481-01 | AZHAR, MOHAMAD | ACEPRE, LLC, SC | $299,953 | ZRG1 |
| 2024 | A Biosinpired Genetically-Expressible Dual-Modality Peptide-Based Probe for Super-Resolution Correlative Light and Electron Microscopy1R41GM153173-01 | LAWRENCE, CHARLES MARTINLEWIS, KEVIN MICHAEL | PHOTON BIOSCIENCES, LLC, WA | $299,812 | ZRG1 |
| 2024 | MECHANICALLY ROBUST 3D-PRINTED MICROCAPILLARY NEEDLES WITH ANTI-CLOGGING CAPABILITIES1R41GM153053-01 | RAND, KINNERET | SEETRUE TECHNOLOGY, LLC, MD | $296,043 | ZRG1 |
| 2024 | RHODA: Rapid Hemoglobin-Oxygen Dissociation Assay1R41HL172662-01 | GALEN, PETERGURKAN, UMUT A. | HEMEX HEALTH, INC., OR | $295,920 | ZRG1 |
| 2024 | Feasibility of Electronic Screening to Identify Risk of Opioid Misuse and Overdose1R41DA060000-01 | FERRARESE, NICK | OPREMS LLC, IL | $295,876 | ZRG1 |
| 2024 | Evaluation of siRNA based drugs as pro-regenerative disease-modifying therapeutics for age-related olfactory loss1R41DC021592-01 | SCHWOB, JAMES E.WYNNE, GRAHAM MICHAEL | RHINO THERAPEUTICS INC, DE | $295,662 | ZRG1 |
| 2024 | Antigen and adjuvant selection for a vaccine against urogenital schistosomiasis, Hematoshield1R41AI181069-01 | GRAY, SEAN ALEXMOLEHIN, ADEBAYO J | PAI LIFE SCIENCES, INC., WA | $295,386 | ZRG1 |
| 2024 | Low-Cost Ultrasound Imaging for In-Home, Rural, and Clinic Care Without The Need For Trained Staff1R41EB034646-01A1 | DAHL, JEREMYRAGHAVAN, RAGHU | SONOVANCE, INC., MD | $294,641 | ZRG1 |
| 2024 | Developing novel Type 1 CRISPR tools for gene editing therapy1R41GM153041-01 | HOU, ZHONGGANG | GENETOBE INC., MI | $293,319 | ZRG1 |
| 2024 | Targeting retinoid acid metabolic pathways to treat noise-induced hearing loss1R41DC021394-01 | DIAZ, PHILIPPE J | DERMAXON, LLC, MT | $290,920 | ZRG1 |
| 2024 | MyDocSaid: Deep Learning for Patient-Centric Record, Summarization, and Analysis of Medical Conversations1R41NR021089-01 | MARHAMATI, NINA | POTENTIA ANALYTICS INC, IL | $284,317 | ZRG1 |
| 2024 | Personal Cooling Garments to Protect at-Risk Patients from Extreme Heat Waves1R41HL172682-01 | IHNFELDT, ROBIN | GENERAL ENGINEERING AND RESEARCH, LLC, CA | $275,765 | ZRG1 |
| 2024 | Development and in vivo validation of a machine learning platform to predict ototoxic potential of pharmaceuticals1R41DC021390-01 | HARKNESS, JOHN H | REWIRE NEUROSCIENCE, LLC, OR | $275,737 | ZRG1 |
| 2024 | Safety of AAV-mediated C1 Esterase Inhibitor Gene Therapy for Hereditary Angioedema1R41AI181097-01 | CRYSTAL, RONALD G | ENYX THERAPEUTICS, LLC, NY | $275,737 | ZRG1 |
| 2024 | Focal seizure monitoring with a consumer wearable: algorithmic development and validation1R41NS130958-01 · under PA-21-262 | CRONE, NATHAN E | EPIWATCH, INC., MD | $275,547 | ZRG1 |
| 2024 | Combating Corneal HSV Infection with Novel Dynasore Analogues1R41EY035879-01 | LAZAROVA, TSVETELINA IVANONOVAST LEGER, ANTHONY J | MEDCHEM PARTNERS, LLC, MA | $180,642 | ZRG1 |
| 2024 | Developing a therapeutic, music-based mobile application to combat neuropsychiatric symptoms in people living with Alzheimer's disease and related dementias1R41AT012152-01A1 | ATASHZAR, SEYED FAROKHRAY, KENDRA | AUTOTUNE ME LLC, NY | $71,980 | ZRG1 |
| 2023 | Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension2R42HL152921-02A1 · under PA-21-262 | LESSING, GARY | INOVODEL, INC., DE | $1,467,953 | ZRG1 |
| 2023 | Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution2R42CA261259-02A1 | LEE, HSIAOJU SHARONMIKHAIL, MICHEL | TREVARX BIOMEDICAL, INC., PA | $1,043,889 | ZRG1 |
| 2023 | Selective targeting of high affinity alpha4 integrins as a safe treatment strategy for IBD2R42DK127869-02A1 | BIEDIGER, RONALD JHOLLAND, GEORGEWOODSIDE, DARREN G | AVIARA PHARMACEUTICALS, INC., TX | $1,036,641 | ZRG1 |
| 2023 | Development of a Wearable Fluorescence Imaging Device for IntraoperativeIdentification of Brain Tumors2R42CA243600-02 | YU, GUOQIANG | BIOPTICSTECHNOLOGY, LLC, KY | $1,027,934 | ZRG1 |
| 2023 | The Rapid-Production of the High-Performance and Affordable Cadmium Telluride and Cadmium Zinc Telluride for Medical Imaging Applications.2R44EB029280-02A1 | FURENLID, LARS RMCCLOY, JOHN SMONTAG, BENJAMINSWAIN, SANTOSH KUMAR | RADIATION DETECTION TECHNOLOGIES, INC., KS | $1,024,886 | ZRG1 |
| 2023 | A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome2R42AI132047-03 · under PA-21-262 | BOTTEN, JASON W.MURAD, JOANA M | CELDARA MEDICAL, LLC, NH | $1,000,000 | ZRG1 |
| 2023 | Treatment of Inflammatory Complications of Respiratory Infection2R42AI162590-02 | PELURA, TIMOTHY J | RESPANA THERAPEUTICS, INC., PA | $1,000,000 | ZRG1 |
| 2023 | Programming Metabolically Fit TILs for Immunotherapy2R42CA239952-02 | MEHROTRA, SHIKHAR | LIPO-IMMUNO TECH, LLC, SC | $1,000,000 | ZRG1 |
| 2023 | Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy2R42HL160429-02 · under PA-21-262 | KULIOPULOS, ATHAN | OASIS PHARMACEUTICALS, MA | $999,799 | ZRG1 |
| 2023 | Real-time Multimodal Diffuse Reflectance and Polarization Imaging Based Nerve Identification in Surgical Field of View2R42EB029888-02 | BABA, JUSTIN | YAYA SCIENTIFIC, LLC, TN | $998,991 | ZRG1 |
| 2023 | SensiTrak: Automated Assessment of Forelimb Sensation2R44NS120748-02 · under PA-21-262 | SANCHEZ, CAMILO ANDRES | VULINTUS, LLC, TX | $982,150 | ZRG1 |
| 2023 | Improved Treatment of Colorectal Cancer with CF102R42CA254834-02A1 | GMEINER, WILLIAM H. | DEEP CREEK PHARMA, LLC, NC | $964,465 | ZRG1 |
| 2023 | Enabling Next Generation Machine Learning for Large Scale Image Analysis2R44EB032722-02A1 | SABIN, GERALD | RNET TECHNOLOGIES, INC., OH | $937,441 | ZRG1 |
| 2023 | Implantable Microarray Probe for Real-Time Glutamate and GABA Detection2R42NS115282-02A1 | ARUMUGAM, PRABHUMOLDOVAN, NICOLAIE ANDREIVETTER, RIO J | ALCORIX, IL | $903,957 | ZRG1 |
| 2023 | Controlled-release Microbeads to Replace Growth Factors in Fetal Bovine Serum2R42GM142345-02 · under PA-21-262 | ROBERTS, KRISTINASTERN, JEFFREY H | STEMCULTURES, LLC, NY | $903,045 | ZRG1 |
| 2023 | A dual-acting small molecule for the treatment of type 1 diabetes2R42DK131839-02A1 | NUNEMAKER, CRAIG SWU, SHIYONG | ASAKE BIOTECHNOLOGY, LLC, OH | $609,183 | ZRG1 |
| 2023 | A non-invasive, automated platform for hemodynamic assessment of patients at risk of heart failure or pulmonary hypertension1R42HL167342-01A1 | ARNOLD, ANTHONYMAHAJAN, AMAN | SENSYDIA CORPORATION, CA | $605,537 | ZRG1 |
| 2023 | Addressing the wireless power problem: A low-power hybrid radio for neuroscience experiments1R43MH135814-01 | GERTH, REBECCA JEANNEMORIZIO, JAMES | SPIKE NEURO LLC, MI | $567,282 | ZRG1 |
| 2023 | CN-105 Improves Functional Outcome After Intracranial Hemorrhage2R42NS108821-02A1 | BENNETT, ELLEN | AEGISCN, LLC, NC | $562,291 | ZRG1 |
| 2023 | Development of a Biomimetic Stentless Pulmonary Heart Valve for the Treatment of Pediatric Congenital Heart Disease1R41HL167502-01A1 | COYAN, GARRETT ND'AMORE, ANTONIO | NEOOLIFE, INC., PA | $553,838 | ZRG1 |
| 2023 | Two-for-one Stroke Thrombectomy: A novel Dual DAC to enhance navigability, lumen size, aspiration efficiency, and persistent flow arrest in mechanical thrombectomy1R41NS129448-01A1 | KALLMES, DAVID F | PIRAEUS MEDICAL, INC., MN | $499,765 | ZRG1 |
| 2023 | High density chronic optogenetic interface for primate brains1R44MH135529-01A1 | ANGELUCCI, ALESSANDRABLAIR, STEVEN MMATHIESON, KEITHNEGI, SANDEEPRIETH, LOREN | BLACKROCK MICROSYSTEMS, UT | $496,413 | ZRG1 |
| 2023 | Restoration of Muscular Function Following Direct Muscle Neurotization1R41NS132734-01 | SOLETTI, LORENZO | RENERVA, LLC, PA | $494,955 | ZRG1 |
| 2023 | Targeted ColQ gene therapy for Congenital Myasthenic Syndromes1R42NS127713-01A1 · under PA-21-262 | MASELLI, RICARDO ANIBALSEPULVEDA, PATRICIO | AMPLO BIOTECHNOLOGY, INC., MD | $493,111 | ZRG1 |
| 2023 | Testing the effects of a selective calpain-2 inhibitor on spontaneous recurrent seizures in mouse models of epilepsy1R41NS130825-01A1 | BAUDRY, MICHELBI, XIAONING | NEURAEGIS, INC., CA | $489,268 | ZRG1 |
| 2023 | Inducible HMGB1 antagonist for viral-induced acute lung injury.1R41HL167254-01 · under PA-21-262 | BLANCO, JORGE CVOGEL, STEFANIE N. | SIGMOVIR BIOSYSTEMS, INC., MD | $488,080 | ZRG1 |
| 2023 | IND-enabling studies for cell therapy in Parkinson's disease1R41NS132678-01A1 | DAADI, MARCEL | NEONEURON, LLC, TX | $465,228 | ZRG1 |
| 2023 | Development of Novel Small Molecule Anti-Fibrotic Agent for the Treatment of Systemic Scleroderma1R41HL167548-01 · under PA-21-262 | ALEGRIA, ESTHER M | APIE THERAPEUTICS, INC., NC | $452,422 | ZRG1 |
| 2023 | Evaluation of growth potential of ice-free vitrified heart valves in a pediatric porcine model.1R41HL169059-01 | RAJAB, TAUFIEK KONRAD | TISSUE TESTING TECHNOLOGIES, LLC, SC | $452,184 | ZRG1 |
| 2023 | Live spike sorting for multichannel and high-channel recordings1R41NS132700-01A1 | KLUG, ACHIMLEI, TIM CHIFONG | POPNEURON LLC, CO | $438,501 | ZRG1 |
| 2023 | Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment1R41NS135658-01 | LI, WEI | SEAK THERAPEUTICS, LLC, TN | $429,932 | ZRG1 |
| 2023 | Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome1R42HL166050-01A1 · under PA-21-262 | KOLLISCH-SINGULE, MICHAELA CHRISTINALUO, JUNTAO | CMTX BIOTECH, INC., NY | $426,744 | ZRG1 |
| 2023 | Optical gearbox enabled high-speed multiphoton microscope1R43MH135716-01 | CUI, MENGWU, TSAIWEI | PHOTOMATRIX, IN | $425,958 | ZRG1 |
| 2023 | Controlled Gradient Release of Biologics: Enhanced Nerve Conduit for Long‐Gap Injury Repair1R41NS130907-01 · under PA-21-262 | ROMERO-ORTEGA, MARIO IGNACIO | PIONEER NEUROTECH INC., MA | $422,015 | ZRG1 |
| 2023 | Developing novel LOX inhibitors to target chemotherapy resistant TNBC1R42CA275622-01A1 | SAHIN, OZGUR | LOXIGEN, INC., SC | $406,500 | ZRG1 |
| 2023 | MT-125 for the Therapeutic Treatment of Glioblastoma1R42CA278293-01A1 | ROSENFELD, STEVEN S | MYOSIN THERAPEUTICS INC., FL | $406,500 | ZRG1 |
| 2023 | Neural organoid models of the immunological microenvironment of glioblastoma for drug discovery applications1R41CA281533-01A1 | LEBAKKEN, CONNIE S | STEM PHARM, INC., WI | $406,500 | ZRG1 |
| 2023 | Light-directed therapy of squamous cell head and neck cancer with a novel dual-acting chemotherapeutic.1R41CA281440-01A1 | HARADA, HISASHIHARTMAN, MATTHEW C | LIGHT SWITCH BIO, LLC, VA | $406,186 | ZRG1 |
| 2023 | Image-based risk assessment to identify women at high-risk for breast cancer1R41CA285182-01 | KHALIL, ANDRE | WAVED MEDICAL LLC, ME | $405,950 | ZRG1 |
| 2023 | 3D microprinting-enabled microinjection needle arrays for enhanced therapeutics delivery into the brain1R41MH135827-01 | RAND, KINNERET | SEETRUE TECHNOLOGY, LLC, MD | $403,847 | ZRG1 |
| 2023 | A decellularized porcine placenta matrix hydrogel for management of radiation-induced proctitis1R41CA272043-01A1 · under PA-21-262 | LI, JIAN JIAN | BRIOPRYME BIOLOGICS, INC., CA | $400,000 | ZRG1 |
| 2023 | Development of drug conjugates of R-spondin peptibodies for the treatment of colorectal cancer1R41CA281553-01 | CUI, JIELIU, QINGYUN | WNTRIX, INC., TX | $400,000 | ZRG1 |
| 2023 | Targeting glioblastoma with CM93, a novel EGFR inhibitor with exceptional brain penetration1R41CA281586-01 | ZHAO, JEAN | CRIMSON BIOPHARM INC, MA | $400,000 | ZRG1 |
| 2023 | Novel Drug Delivery Platform as Medical Countermeasure for treatment of Gastrointestinal Radiation Damage1R41CA272078-01A1 | MARSH, SPENCER REID | TINY CARGO COMPANY, THE, VA | $400,000 | ZRG1 |
| 2023 | Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)1R42CA281707-01 | NAGY, JON OWENTRICHE, TIMOTHY J. | NANOVALENT PHARMACEUTICALS, INC., MT | $400,000 | ZRG1 |
| 2023 | Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy1R42CA285234-01 | DEMETRIOU, MICHAELZHOU, RAYMOND WENHOU | GLYTR THERAPEUTICS, INC., CA | $400,000 | ZRG1 |
| 2023 | Genetic Biocontainment Switch to Improve the Safety of Drug Detoxifying Bacteria in Preventing Chemotherapy-induced Diarrhea1R41CA275454-01A1 | CHAN, TSZ YAN CLEMENTHU, MINGSINGH, RASHIM | SANARENTERO LLC, TX | $399,999 | ZRG1 |
| 2023 | A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform1R41CA278184-01A1 | BLOCK, MATTHEW STEPHENWANG, CHUN | TREKKA THERAPEUTICS, LLC, MN | $399,979 | ZRG1 |
| 2023 | GENOMICE (Game Exploring Nuances in Offspring to Master Interactions of Chromosome Expression)1R41HG013076-01A1 | AARON, ERICFREEDMAN, RICHARD GABRIELTILDEN, ANDREA R | SMART INFORMATION FLOW TECHNOLOGIES, MN | $399,948 | ZRG1 |
| 2023 | Human specific STING agonists for the treatment of cancer1R41CA275637-01A1 | AHN, JEONGHYUNBARBER, GLEN N | STINGINN, LLC, FL | $399,812 | ZRG1 |
| 2023 | Water-based liquid embolic agent for the treatment of vascular rich tumors1R41CA277860-01A1 | YUKI, ICHIRO | AQUATEX MEDICAL, INC., CA | $399,528 | ZRG1 |
| 2023 | An IGF-1R-targeting peptide drug conjugate for targeted treatment of atypical teratoid/rhabdoid tumors1R41CA285172-01 | GOLDSTEIN, NEIL | NIGHTHAWK BIOSCIENCES, INC., NC | $399,110 | ZRG1 |
| 2023 | Synergize a novel homologous recombination inhibitor with DNA damagingagents in TNBC1R41CA281511-01A1 | NEUMANN, CAROLA ANKESCHOPFER, FRANCISCO JOSE | CREEGH PHARMACEUTICALS, INC., PA | $398,728 | ZRG1 |
| 2023 | Preclinical Evaluation of a Novel ADAM10 Modulator to Treat ColorectalCancer1R41CA278070-01A1 | PREMSRIRUT, PREM KHOVABUTR | MIRIMUS, INC., NY | $397,916 | ZRG1 |
| 2023 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease1R41DK138578-01 | SCHULTZ, KENNETH | TRETHERA CORPORATION, CA | $395,119 | ZRG1 |
| 2023 | A novel dual-carrier ultrasmall nanomedicine for the treatment of stroma-rich pancreatic cancer1R41CA285174-01 | EICHINGER, KATHERINE MARIE | DUO ONCOLOGY INC, PA | $394,967 | ZRG1 |
| 2023 | Therapeutic targeting of FKBP51 for the prevention of stress-induced preterm birth1R41HD113465-01 | FRIEND, DAVID R | DARE BIOSCIENCE, INC., CA | $384,972 | ZRG1 |
| 2023 | Closed-loop laryngeal pacing for voice restoration1R41DC020869-01A1 | HEATON, JAMES T.HIATT, SCOTT | RIPPLE, LLC, UT | $382,366 | ZRG1 |
| 2023 | A Novel Therapeutic to Promote Corneal Repair1R42EY034791-01A1 | CHUCK, ROY SKRAMER, ADAM HILDYARDSHARP, DAVID JAMES | MICROCURES, INC., CA | $380,000 | ZRG1 |
| 2023 | Towards intra-operative guidance in brain tumor surgery using real-time resting-state functional MRI1R42NS134505-01 | DENNIG, DIETER WPOSSE, STEFAN | NEURINSIGHT, LLC, NM | $378,233 | ZRG1 |
| 2023 | Novel Small Molecule Drug Candidate for the Prevention of Bronchopulmonary Dysplasia1R41HD112274-01 | KOLLISCH-SINGULE, MICHAELA CHRISTINA | CMTX BIOTECH, INC., NY | $376,752 | ZRG1 |
| 2023 | THERAPY FOR ALCOHOL USE DISORDER1R41AA031392-01 | SELTZMAN, HERBERT H | ARTIAM BIO INC., NC | $368,673 | ZRG1 |
| 2023 | Endoscopy-assisted intracochlear access via ultrasharp-microneedles1R41DC021128-01 | AKSIT, AYKUTLALWANI, ANIL K | HAYSTACK MEDICAL, INC., NY | $350,033 | ZRG1 |
| 2023 | Nanopore Array for Multiparameter Analysis of Single Extracellular Vesicles1R41GM151921-01 | GERMAN, SEAN | ELECTRONIC BIOSCIENCES, INC., CA | $349,996 | ZRG1 |
| 2023 | Prodrugs of potent and selective protease inhibitors as tauopathy therapeutics1R41NS134497-01 | ASHE, KAREN HWALTERS, MICHAEL A. | MYRIEL, INC., MN | $349,992 | ZRG1 |
| 2023 | Sulfated Carbohydrates for the Treatment of Periodontitis1R41DE032276-01A1 | MIGUEZ, PATRICIA | GLYCAN THERAPEUTICS CORPORATION, NC | $347,537 | ZRG1 |
| 2023 | MTI-301 a SCD1 inhibitor for the treatment of NASH1R41DK131705-01A1 | GELDENHUYS, WERNERHAZLEHURST, LORI | MODULATION THERAPEUTICS, INC., WV | $344,919 | ZRG1 |
| 2023 | Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy1R41EY034773-01 · under PA-21-262 | ANDLEY, USHA PHAMRAH, PEDRAM | AFFIRMED PHARMA, LLC, TX | $341,302 | ZRG1 |
| 2023 | Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Peripheral Artery Disease1R41HL170875-01 | HUANG, NGAN F.LEE, JI EUN | SERINA THERAPEUTICS, INC., CA | $340,956 | ZRG1 |
| 2023 | Improving parent-adolescent communication about sexual and reproductive health1R41HD112212-01A1 | WIDMAN, LAURA M. | TEEN HEALTH RESEARCH, INC., NC | $340,143 | ZRG1 |
| 2023 | A novel producer cell line for more efficient manufacturing of viral vector systems1R41TR004231-01A1 · under PA-21-262 | HAMM, ELAINE | CLAIRIGENE, LLC, NC | $330,532 | ZRG1 |
| 2023 | CRISPR-Cas Editing as a Genetic Cure for Autosomal Dominant Polycystic Kidney Disease1R41DK138689-01 | MAXIM, DEMETRIOS STHAKOR, AVNESH SINH | NEPHROGEN INC., NY | $325,000 | ZRG1 |
| 2023 | Exploiting translation elongation for improved biologics manufacturing1R41TR004774-01 | BYRNE, SHANEDEDON, PETER C | CODOMAX INC., MA | $324,999 | ZRG1 |
| 2023 | A novel platform for synthetic generation and statistical obfuscation of tabular clinical data, simulated images, and machine-generated text1R41TR004515-01 | SHETTY, RONAK | GRAYRAIN, LLC, MI | $324,632 | ZRG1 |
| 2023 | The development of the Clinical Picture Maker, a novel video platform to aid the diagnosis and treatment of SCN2A-related disorders, and other rare diseases.1R41TR004790-01 | TIRANOFF, LOUISE MARY | TIRANOFF PRODUCTIONS, LLC, NY | $321,945 | ZRG1 |
| 2023 | Leptin Receptor Agonist to Treat Sleep Disordered Breathing1R41HL167326-01 · under PA-21-262 | KRAUS, CARL NEILPOLOTSKY, VSEVOLOD Y | ARREVUS, INC., NC | $319,944 | ZRG1 |
| 2023 | Using in-vivo Real-time Biosensor to Evaluate Prodrugs Designed to Prolong Therapeutic Effects for Smoking Cessation.1R41DA056334-01A1 · under PA-21-262 | BETLEY, JOHN NICHOLASLEE, PETER H | SPACERX LLC, VA | $318,605 | ZRG1 |
| 2023 | Evaluation of recombinant bovine lactoferrin and N-linked glycan effects on infant gut health and immunity1R41HD114267-01 | FEHER CASTAGNA, VANESSA PATRICIAJIANG, RULAN | TURTLETREE LABS INC., CA | $311,323 | ZRG1 |
| 2023 | Development of a treatment for durable remission of HIV using transposon engineered CAR-T and NK cells1R41AI170186-01A1 · under PA-21-262 | ATHANASIOU, MARIA CONSTANCESKINNER, PAMELA J | MARPAM PHARMA, LLC, MN | $306,500 | ZRG1 |
| 2023 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus1R41AI179213-01 | SCHULTZ, KENNETH | TRETHERA CORPORATION, CA | $305,135 | ZRG1 |
| 2023 | Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis1R41AI179525-01 | PULSIPHER, ABIGAIL | GLYCOMIRA, LLC, UT | $304,921 | ZRG1 |
| 2023 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)1R41AI179191-01 | SCHULTZ, KENNETH | TRETHERA CORPORATION, CA | $304,461 | ZRG1 |
| 2023 | SPNS2 inhibitors as renal fibrosis therapy1R41DK136371-01A1 | SANTOS, WEBSTER L | S1P THERAPEUTICS INC., VA | $301,373 | ZRG1 |
| 2023 | miRNA-Nanotechnology as a novel regenerative therapy for lymphangioleiomyomatosis1R41HG013603-01A1 | BRENNER, JACOBKRYMSKAYA, VERA PPLEIMES, DIRK | BIOSPUTNIK LLC, NY | $301,016 | ZRG1 |
| 2023 | Genetic adjuvants to elicit neutralizing antibodies against HIV1R43MH133246-01 · under PA-21-262 | HARTIGAN-O'CONNOR, DENNIS J.SPARGER, ELLEN ELIZABETH | TENDEL THERAPIES INC., CA | $300,930 | ZRG1 |
| 2023 | Novel therapeutic intervention of early-stage T1D1R41DK133051-01A1 | CHEN, XIAN | TRANSCHROMIX, LLC., NC | $300,670 | ZRG1 |
| 2023 | Developing a new aspiration catheter solution for the treatment of large and medium vessel occlusions1R41NS132732-01 | BECKER, TIM | ANEUVAS TECHNOLOGIES, INC., AZ | $300,527 | ZRG1 |
| 2023 | Substance Use Disorder Artificially Intelligent chatbot for screening, assessment & referral: SUD Bot1R41DA059275-01 | BULL, SHEANA S | CLINIC CHAT LLC, CO | $300,526 | ZRG1 |
| 2023 | Next-generation nanomedicine for acute ischemic stroke1R41NS130812-01 · under PA-21-262 | BRENNER, JACOB | NANOMUSE, LLC, NJ | $300,454 | ZRG1 |
| 2023 | An immunotherapeutic IgY formulation against norovirus diarrhea1R41AI172485-01A1 | GOEPP, JULIUS G | SCALED MICROBIOMICS, LLC, MD | $300,000 | ZRG1 |
| 2023 | Therapeutic Agents Targeting Cryptococcal Infections1R41AI172564-01A1 | WRIGHT, DENNIS L. | QUERCUS MOLECULAR DESIGN, LLC, CT | $300,000 | ZRG1 |
| 2023 | Hepatoselective Dihydroquinolizinone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection1R41AI177204-01 | DU, YANMING | HARLINGENE LIFE SCIENCES LLC, PA | $300,000 | ZRG1 |
| 2023 | Leptospirosis Vaccine Development1R41AI174377-01A1 | DEVILLERS, CARLA | LUNA BIOSCIENCE, INC., CT | $300,000 | ZRG1 |
| 2023 | Precision Glycoengineering of an HCV Envelope-Based Nanoparticle Vaccine1R41AI179330-01 | HORRIGAN, STEPHEN KEVIN | NEUIMMUNE BIOLOGICS, INC., MD | $300,000 | ZRG1 |
| 2023 | A novel therapeutic for the treatment of biofilms in periprosthetic joint infections1R41AI179543-01 | GILBERTIE, JESSICA | QENTOROS, LLC, VA | $300,000 | ZRG1 |
| 2023 | Development of small molecule Protease-activated-receptor-2 antagonists as oral asthma therapeutics1R41HL169048-01A1 | BOITANO, SCOTTDEFEA, KATHRYN ANNE | PARMEDICS, INC., CA | $300,000 | ZRG1 |
| 2023 | Development of a first-in-class antiviral to address CMV drug resistance in immunocompromised patients1R42AI174554-01A1 | RODICK, ROBERTWEINBERGER, LEOR S | VXBIOSCIENCES, INC., CA | $300,000 | ZRG1 |
| 2023 | Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections1R41AI177227-01A1 | WYCOFF, KEITH | PLANET BIOTECHNOLOGY, INC., CA | $300,000 | ZRG1 |
| 2023 | Recombinant E-NTPDase for shock1R41GM151882-01 | HASKO, GEORGE | PURINE PHARMACEUTICALS, INC., NJ | $299,999 | ZRG1 |
| 2023 | Novel Combination Therapy for Treatment and Prevention of PulmonaryLymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC)1R41HL164196-01A1 | KRYMSKAYA, VERA PPLEIMES, DIRK | BIOSPUTNIK LLC, NY | $299,997 | ZRG1 |
| 2023 | Targeting macrophage maladaptation for bacterial sepsis treatment1R41AI174362-01A1 | ZHU, XUEWEI | ACEPRE, LLC, SC | $299,982 | ZRG1 |
| 2023 | Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development1R41HL167327-01 · under PA-21-262 | HOFFMAN, STANLEY R | FIBROTHERAPEUTICS, INC., SC | $299,972 | ZRG1 |
| 2023 | Optimizing the synthesis of[18F]FTMP for commercial distribution1R41EB034141-01 · under PA-21-262 | SELLMYER, MARK A | VELLUM BIOSCIENCES LLC, PA | $299,927 | ZRG1 |
| 2023 | Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk1R41HL167303-01 · under PA-21-262 | GRAY, BRIAN DAVID | MOLECULAR TARGETING TECHNOLOGIES, INC., PA | $299,890 | ZRG1 |
| 2023 | Dialysate regeneration system based on photo-electrochemical urea oxidation and reactive adsorption to enable portable hemodialysis1R41DK137677-01 | FULKERSON, BARRY | KULEANA TECHNOLOGY, INC., WA | $299,646 | ZRG1 |
| 2023 | Development of a novel sensor for the real-time measurement of mitral coaptation force1R41HL167401-01 · under PA-21-262 | GRINBERG, DANIELMEDIGO, ANTHONYRAPOPORT, BENJAMIN ISAAC | MITRALPRINT INC., MI | $299,577 | ZRG1 |
| 2023 | Developing RNA therapeutics for rare neurodevelopmental disorders1R42HD111138-01A1 | LOTTI, FRANCESCO | DAYI THERAPEUTICS, INC., TX | $299,546 | ZRG1 |
| 2023 | Innovative medical device to treat nonunion fracture for older adults1R41AG080953-01A1 | CHEN, MOGUAN, JIANJUNSHEN, JIE | WNT SCIENTIFIC, LLC, NY | $299,428 | ZRG1 |
| 2023 | Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis1R42AI179344-01 | ROEMER, TERRY | PROKARYOTICS, INC., NJ | $299,326 | ZRG1 |
| 2023 | Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis1R41HL167504-01A1 | BOGATKEVICH, GALINA SSILVER, RICHARD M. | FIBROBIOLOGICS, LLC, SC | $299,295 | ZRG1 |
| 2023 | Structurally engineered furan fatty acids for the treatment of dyslipidemia and cardiovascular disease1R41HL167544-01A1 · under PA-21-262 | SCHOPFER, FRANCISCO JOSE | FURANICA, INC., PA | $299,169 | ZRG1 |
| 2023 | A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection1R42AI174369-01 · under PA-21-262 | ALVERDY, JOHN C | COVIRA SURGICAL, IL | $299,066 | ZRG1 |
| 2023 | Amadorins as a Novel Oral Therapeutic for Diabetic Retinopathy1R41EY034725-01 · under PA-21-262 | KHALIFAH, RAJA G | PRAETEGO, INC., NC | $298,940 | ZRG1 |
| 2023 | Precision MRI with a Novel Protein Contrast Agent for Early Detection and Staging of Lung Fibrosis1R41HL170898-01 | YANG, JENNY J. | INLIGHTA BIOSCIENCES, LLC, GA | $298,840 | ZRG1 |
| 2023 | Targeting Myosin to Treat Polycystic Kidney Disease1R41DK136452-01 | FU, HONGXIA | PLUREXA LLC, WA | $298,326 | ZRG1 |
| 2023 | Gelbrane: Combined Gel and Membrane for Robust Western Blotting1R41GM151910-01 | BIRTWISTLE, MARC R. | BLOTTING INNOVATIONS, LLC, SC | $297,664 | ZRG1 |
| 2023 | An R2 non-neuroinvasive herpes simplex virus type 2 vaccine1R42AI177202-01 | SMITH, GREGORY ALLAN | THYREOS, INC, IL | $297,493 | ZRG1 |
| 2023 | Development of the HC2099 series of MmpL3 inhibitors to treat tuberculosis1R41AI167105-01A1 | VRBANAC, JOHN JAMES | TARN BIOSCIENCES, INC., MI | $297,136 | ZRG1 |
| 2023 | Evaluating the efficacy of Butyric acid pro-drug nanoparticle in retinal neuroprotection1R41EY034735-01 · under PA-21-262 | BISWAL, MANAS R | NUTRIFORWARD, LLC, TX | $296,790 | ZRG1 |
| 2023 | Vitiligo topical treatment applying a potent, highly selective MC1R agonist1R41AR083311-01 | ABDEL-MALEK, ZALFA | MC1R VENTURES LLC, OH | $295,913 | ZRG1 |
| 2023 | Practice Wellness: Equipping home visitors with skills in reflective coaching, parent mediated child development, and occupational wellness to strengthen child outcomes among low-resourced families1R41HD114332-01 | JOHNSON-SHELTON, DEBORAH | SAAVSUS, INC., OR | $295,787 | ZRG1 |
| 2023 | Development of a Urine Test for At-Home Monitoring of Blood Phe Levels for PKU1R41HD112228-01A1 | CHAMPAIGNE, KEVIN D | CIRCA BIOSCIENCE, LLC, SC | $295,724 | ZRG1 |
| 2023 | Membrane repair as a therapeutic intervention for treating Becker Muscular Dystrophy1R42AR083329-01 | WEISLEDER, NOAH | MYOFINITY BIOSCIENCES INC, MA | $295,536 | ZRG1 |
| 2023 | Feasibility of app-delivered circadian synchronization therapy with light in a cohort of pregnant women1R41HD114317-01 | WALCH, OLIVIA | ARCASCOPE, INC, VA | $295,128 | ZRG1 |
| 2023 | Prevention and mitigation of acute traumatic coagulopathy and bleeding1R41HL169120-01 | MOSNIER, LAURENT O | HEMATHERIX, LLC, CA | $295,000 | ZRG1 |
| 2023 | A Machine Learning Algorithm to Assess Functional "Brain Age" from an In-Home EEG Sleepband1R41AG085773-01 | COMERFORD, MICHAEL | NEUROGENECES, INC., NM | $295,000 | ZRG1 |
| 2023 | Clusterin Targeting of Ocular Surface Disease1R41EY034396-01A1 | FINI, M ELIZABETHMASLI, SHARMILA | PROTERIS BIOTECH, INC., CA | $294,662 | ZRG1 |
| 2023 | Novel Adipose Targeted Gene Therapy for Lipodystrophy1R41DK138551-01 | CAO, LEIHAWKINS, AL | ZVELT THERAPEUTICS INC., OH | $293,842 | ZRG1 |
| 2023 | Structurally engineered N-acyl amino acids for the treatment of NASH1R41DK137711-01 | SCHOPFER, FRANCISCO JOSE | FURANICA, INC., PA | $293,543 | ZRG1 |
| 2023 | Systemic Transplantation of MyoPAXon: IND Enabling Studies for the Treatment of DMD1R42AR083779-01 | KYBA, MICHAELPERLINGEIRO, RITA C. R. | MYOGENICA INC., MN | $292,719 | ZRG1 |
| 2023 | Advanced optics to unlock large field-of-view multiphoton imaging for neuroscience and beyond1R41MH136563-01 | SMITH, SPENCER LAVERE | PACIFIC OPTICA, INC., CA | $292,576 | ZRG1 |
| 2023 | Genome Editing Therapy for Usher Syndrome Type 31R42EY035582-01 | IANNUZZI, MICHAEL CYANG, DONGSHAN | GENETOBE INC., MI | $289,895 | ZRG1 |
| 2023 | IgE-suppressing small molecule compound Xanthopurpurin analog for multiple food allergies1R41AI172572-01A1 | LI, XIU-MINYANG, NAN | GENERAL NUTRACEUTICAL TECHNOLOGY, LLC, NY | $289,622 | ZRG1 |
| 2023 | Time-resolved laser speckle contrast imaging of resting-state functional connectivity in neonatal brain1R42MH135825-01 | YU, GUOQIANG | BIOPTICSTECHNOLOGY, LLC, KY | $289,075 | ZRG1 |
| 2023 | Preclinical evaluation of SERCA2 allosteric activators for pancreatic β-cell protection in diabetes.1R41DK134247-01A1 | DAHL, RUSSELL | NEURODON LLC, IN | $286,348 | ZRG1 |
| 2023 | Demonstrating miniaturized production of a KOR PET tracer as a proof-of-concept for low-cost distribution of nascent PET neurotracers1R41DA059980-01 | JONES, JASON | DROPLETPHARM INC., CA | $286,331 | ZRG1 |
| 2023 | Development of Nicotinamide-Riboside plus Pterostilbene as a Disease Modifying Osteoarthritis Therapeutic1R41AR082748-01 | BRYAN, RUDELLINGER, RYAN WILLIAM | ELYSIUM HEALTH, INC., NY | $283,071 | ZRG1 |
| 2023 | Addressing bone marrow lesions that compromise osteochondral tissue repair1R41AR083778-01 | WILLARD, VINCENT P | CYTEX THERAPEUTICS INC., NC | $282,265 | ZRG1 |
| 2023 | Advanced Quantitative Magnetic Resonance Imaging Phantoms for Nonalcoholic Fatty Liver Disease1R41EB033717-01A1 | BRITTAIN, JEAN H.REEDER, SCOTT B. | CALIMETRIX, LLC, WI | $282,252 | ZRG1 |
| 2023 | Development of Antisense Oligonucleotides to Regulate Gamma' Fibrinogen Levels1R41HL170874-01 | FARRELL, DAVID HENRY | GAMMA THERAPEUTICS, INC., OR | $277,710 | ZRG1 |
| 2023 | Wearable Array for Ultrasound Stimulation on the Retina1R41EY035609-01 | CHABOK, HAMID REZAZHOU, QIFA | PHONONZ INC, CA | $276,306 | ZRG1 |
| 2023 | Production of radiometal-based radiopharmaceuticals at a clinical scale via droplet-scale radiochemistry1R41EB034168-01A1 | JONES, JASON | DROPLETPHARM INC., CA | $275,773 | ZRG1 |
| 2023 | Recognition of O-GlcNAc Modified Proteins Using Site-Specific Antibodies1R43HL166086-01A1 | POPOV, MARLA | GLYCOSCIENTIFIC, LLC, GA | $275,767 | ZRG1 |
| 2023 | Audiom: Developing an Indoor Non-Visual Mapping System1R41EY034411-01A1 | BIGGS, BRANDON | XR NAVIGATION INC., CA | $275,766 | ZRG1 |
| 2023 | Deep-UV Microscopy for Real-Time Adequacy Analysis of Bone Marrow Aspirates1R41EB035057-01 | ROBLES, FRANCISCO E | CELLIA SCIENCE, INC., AR | $275,766 | ZRG1 |
| 2023 | Novel probiotics to mitigate xenobiotic toxicity through microbial biotransformation1R41ES034979-01A1 | MOFRAD, MOHAMMAD RKSHIRAZI, FATEMEHSOHEILYPOUR, MOHAMMAD | NEXILICO, INC., CA | $275,765 | ZRG1 |
| 2023 | Feasibility and design of a novel smartphone app to deliver blood pressure-lowering inspiratory muscle strength training1R41HL167375-01A1 | SEALS, DOUGLAS R | KLEIN BUENDEL, INC., CO | $275,764 | ZRG1 |
| 2023 | Ultrasound-coupled Electrical Impedance Tomography for Sarcopenia Assessment1R41AG082635-01A1 | HALTER, RYAN JOSEPH | RYTEK MEDICAL, INC., NH | $275,762 | ZRG1 |
| 2023 | Protection of transplanted heart function by regulation of Na/K pump activity1R41HL165958-01A1 | CHEN, WEILIU, RUISHENG | WR BIOTECH, LLC, FL | $275,739 | ZRG1 |
| 2023 | Translational development of novel CRISPR approach to treat genomic duplications1R41AR082205-01A1 | LEK, MONKOL | MYOFINITY BIOSCIENCES INC, MA | $275,651 | ZRG1 |
| 2023 | Biomarkers for Brain Resetting as an Assistive Tool in the Treatment of Status Epilepticus1R41NS132627-01 | JASSEMIDIS, LEONIDAS D | EPIFOCUS LLC, AZ | $275,572 | ZRG1 |
| 2023 | Physics-informed Machine Learning approach for a selective, sensitive, and rapid sensor for detecting unsafe levels of carcinogenic/toxic VOCs1R41ES034936-01 · under PA-21-262 | ATTARIANI, HAMED | PROMETHEUS TECHNOLOGIES, LLC, OH | $275,554 | ZRG1 |
| 2023 | Glycan biomarker panels in liquid biopsies for predicting treatment response in lupus nephritis1R41DK135167-01 · under PA-21-262 | CASTELLINO, STEPHENNOWLING, TAMMY (TAMARA) | GLYCOPATH, INC, SC | $275,397 | ZRG1 |
| 2023 | Enhanced CRISPR gene editing in pluripotent stem cells using carbon nanotube arrays1R41GM150320-01 | DICKERSON, IAN MSCHRLAU, MICHAEL GEORGE | ADVANCED GENE TRANSFER COMPANY, INC., NY | $275,045 | ZRG1 |
| 2023 | Structure-based computational engineering of saCas9 PAM requirement1R41GM149016-01A1 | HUANG, XIAOQIANGXIA, XIAOFENG | ATGC, INC., MI | $274,955 | ZRG1 |
Showing the 200 most recent of 1,925 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.